INTRODUCTION
============

Membranous nephropathy (MN) is among the most common causes of nephrotic syndrome in adults worldwide \[[@sfz036-B1]\]. For decades it has been a histological diagnosis with two distinct entities: primary or autoimmune membranous nephropathy (PMN) and secondary MN. Despite their histological similarities, the pathogenesis and treatments differ greatly, meaning that differentiating between the two conditions is essential. Secondary MN is associated with a multitude of conditions such as malignancy, viral infections such as hepatitis B and C, medications and other autoimmune conditions such as lupus and toxins \[[@sfz036-B7]\]. As such, management is aimed at treating the underlying condition.

PMN, originally known as idiopathic MN, has always been considered an autoimmune disease, although the offending antibody remained elusive until the discovery of antibodies to the M-type phospholipase receptor 1 (anti-PLA~2~R) in 2009 \[[@sfz036-B10]\]. This immunoglobulin G class antibody is found in ∼75% of patients with PMN and has high affinity for podocytes \[[@sfz036-B10], [@sfz036-B16], [@sfz036-B17]\]. There is now considerable evidence to suggest that not only is it a sensitive biomarker of disease activity, but also pathogenic in its own right. High titres are known to correlate with disease activity, and for patients who go into remission, the anti-PLA~2~R levels decrease months before clinical signs, such as a reduction in proteinuria. The converse is also true with relapse predated by an increase in antibody levels \[[@sfz036-B13], [@sfz036-B14], [@sfz036-B18]\]. The antibody level can also help to provide some level of prognostication, with high titres associated with a worse renal outcome compared with low titres \[[@sfz036-B13]\]. If treatment does not result in antibody negativity, patients are left with a high risk of relapse. In fact, if treatment does not result in antibody negativity, then they are left with a high risk of relapse and a reduction in anti-PLA~2~R level strongly predicts remission \[[@sfz036-B18], [@sfz036-B20], [@sfz036-B22]\].

The benefit of regular anti-PLA~2~R testing led to the introduction of the first quantitative anti-PLA~2~R enzyme-linked immunosorbent assay (ELISA) test, which was developed in Manchester and became available across the northwest of England towards the end of 2011 \[[@sfz036-B13]\]. Since then a commercial anti-PLA~2~R test has been developed and is now readily available internationally \[[@sfz036-B23]\]. Prior to the development of these ELISAs, PMN was a diagnosis of exclusion. Given the association of secondary MN with malignancy and given the disease itself is generally a disease of middle age and older, many patients undergo a number of invasive procedures in order to rule out neoplastic disease. At present, there is no universally accepted consensus on the investigative pathway for primary or secondary MN. In patients with PMN, this results in many being procedures performed, with normal findings, at a cost not only to the patient in terms of quality of life, but also a societal cost to health care systems with limited resources.

Hypothesis
----------

With the anti-PLA~2~R test becoming more ubiquitous, the introduction of anti-PLA~2~R antibody testing leads to a reduction in the frequency of investigations for patients with MN.

MATERIALS AND METHODS
=====================

All adult patients with biopsy-proven MN between 2009 and 2014 from three large teaching hospitals in the northwest of England covering a population of ∼7 million were included in the study. Patients were excluded if biopsy was not conclusive of MN. Patients were identified from patient records and histopathology results from each centre.

Day 0 was taken as the date of renal biopsy. Records were reviewed for investigations that took place 6 months prior to and 6 months following the biopsy date to see if these were normal or identified a secondary cause of MN. Investigations included viral and autoimmune screens, X-rays, computed tomography (CT) scans, magnetic resonance imaging (MRI), positron emission tomography (PET) scans, ultrasound scans, upper and lower gastrointestinal (GI) endoscopies and cystoscopies. Investigations were excluded if they were not performed in relation to the diagnosis of primary versus secondary MN.

Records were also interrogated to determine if a patient had an anti-PLA~2~R test and at what date. The result was only included if the sample was also taken within 6 months of the date of biopsy. A positive anti-PLA~2~R test was taken as \>40 U/mL for the ELISA and a titre of \>1:10 for the Euroimmun indirect immunofluorescence test (IIFT). A negative ELISA was taken as \<40 U/mL and a titre of ≤ 1:10 for the Euroimmun IIFT \[[@sfz036-B13]\].

Costs were assigned to each investigation in pounds sterling and taken from the National Health Service (NHS) reference costs for 2015--16 \[[@sfz036-B24]\]. For chest and abdominal X-rays, the costs were taken from the NHS England National Tariff for 2015--16 \[[@sfz036-B25]\]. The cost of anti-PLA~2~R testing was not included ([Table 1](#sfz036-T1){ref-type="table"}).

###### 

Cost of investigations

  Investigation      Mean value    LQR       UQR            Source
  ----------------- ------------ -------- --------- ----------------------
  Hepatitis B           6.42       4.02     7.65     DAPS06 NHS ref costs
  Hepatitis C           6.42       4.02     7.65     DAPS06 NHS ref costs
  HIV                   6.42       4.02     7.65     DAPS06 NHS ref costs
  RF                    6.42       4.02     7.65     DAPS06 NHS ref costs
  ds-DNA                6.42       4.02     7.65     DAPS06 NHS ref costs
  ANA                   6.42       4.02     7.65     DAPS06 NHS ref costs
  Complement            6.42       4.02     7.65     DAPS06 NHS ref costs
  PSA                   1.18       0.78     1.39     DAPS04 NHS ref costs
  ANCA                  6.42       4.02     7.65     DAPS06 NHS ref costs
  TFTs                  1.18       0.78     1.39     DAPS04 NHS ref costs
  Chest X-ray          25.00                           National tariff
  Abdominal X-ray      25.00                           National tariff
  CT head              93.93      65.19    115.59    RD20A NHS ref costs
  CT thorax            102.50     70.75    134.97    RD21A NHS ref costs
  CT abdomen           102.50     70.75    134.97    RD21A NHS ref costs
  CT TAP               120.70     88.30    138.91    RD26Z NHS ref costs
  MRI                  145.14     113.26   173.53    RD01A NHS ref costs
  PET                  798.20     430.64   1213.54   RN07A NHS ref costs
  OGD                  352.21     322.20   432.22    FZ60Z NHS ref costs
  Colonoscopy          371.27     236.45   521.90    FZ51Z NHS ref costs
  Sigmoidoscopy        207.69     152.04   247.24    FZ54Z NHS ref costs
  USS abdomen          50.62      38.54     60.44    RD40Z NHS ref costs
  Cystoscopy           151.71     101.68   175.50    LB72A NHS ref costs

All costs in British pound sterling. NHS ref costs, National Health Service reference costs 2015--16 \[[@sfz036-B24]\]; National tariff, National Health Service non-mandatory currencies and prices 2015--16 \[[@sfz036-B25]\]; LQR, lower quartile range; UQR, upper quartile range; HIV, human immunodeficiency virus; RF, rheumatoid factor; dsDNA, double-stranded deoxyribonucleic acid; ANA, anti-nuclear antibody; ANCA, antineutrophil cytoplasmic antibody; PSA, prostate-specific antigen; CT, computed tomography; MRI, magnetic resonance imaging; PET, positron emission tomography; OGD, oesophagogastroduodenoscopy; USS, ultrasound scan; TFTs, thyroid function tests; TAP, thorax, abdomen and pelvis.

For each patient, a total cost was determined for the investigations they underwent, using the resource costs as mentioned above. The mean cost and number of investigations with 95% confidence intervals (CIs) were calculated with standard bootstrapping using 10 000 samples with replacement \[[@sfz036-B26], [@sfz036-B27]\].

The number of investigations and the cost of investigations per year were then analysed based on the presence of a positive anti-PLA~2~R versus a negative test or no sample taken. Significance was calculated using the Student\'s *t*-test and defined as \<0.05. All analyses were carried out using R statistical software version 3.4.3 (R Foundation for Statistical Computing, Vienna, Austria) \[[@sfz036-B28]\].

RESULTS
=======

A total of 184 patients across the three hospitals were included. The mean age of our cohort at diagnosis was 58 years, with a predominance of male patients (64%). A total of 80 (43%) patients did not undergo anti-PLA~2~R testing within 6 months of the date of biopsy and 104 (57%) patients did have an anti-PLA~2~R test within 6 months of the date of biopsy; 66 (63% of those tested) had a negative test and 38 (37% of those tested) had a positive test ([Table 2](#sfz036-T2){ref-type="table"} and [Figure 2](#sfz036-F2){ref-type="fig"}). Of the 184 patients included in the study, 21 (11.4%) were confirmed as secondary MN. Of these 21 patients, 9 were tested for anti-PLA~2~R and all were negative.

###### 

Demographics

  Parameter                              No anti-PLA~2~R   Negative anti-PLA~2~R   Positive anti-PLA~2~R     Total
  ------------------------------------- ----------------- ----------------------- ----------------------- ------------
  Patients                                   80 (43)              66 (36)                 38 (21)          184 (100)
  Age at diagnosis (years), mean (SD)      59 (15.58)           57 (15.64)              57 (13.19)         58 (15.10)
  Gender                                                                                                  
   Female                                    32 (40)              24 (36)                 11 (29)           67 (36)
   Male                                      48 (60)              42 (64)                 27 (71)           117 (64)
  Hepatitis B                                                                                             
   Negative test                             38 (48)              28 (42)                 13 (34)           79 (43)
   No test                                   42 (52)              38 (58)                 25 (66)           105 (57)
  Hepatitis C                                                                                             
   Negative test                             38 (48)              28 (42)                 12 (32)           78 (42)
   No test                                   42 (52)              38 (58)                 26 (68)           106 (58)
  HIV                                                                                                     
   Negative test                             17 (21)              20 (30)                 12 (32)           49 (27)
   No test                                   63 (79)              46 (70)                 26 (68)           135 (73)
  Rheumatoid factor                                                                                       
   Negative test                             31 (39)              17 (26)                 8 (21)            56 (30)
   No test                                   48 (60)              48 (73)                 30 (79)           126 (68)
   Positive test                              1 (1)                1 (2)                   0 (0)             2 (1)
  Anti-dsDNA                                                                                              
   Negative test                             44 (55)              44 (67)                 26 (68)           114 (62)
   No test                                   35 (44)              22 (33)                 12 (32)           69 (38)
   Positive test                              1 (1)                0 (0)                   0 (0)             1 (1)
  ANA                                                                                                     
   Negative test                             61 (76)              53 (80)                 29 (76)           143 (78)
   No test                                   18 (22)              12 (18)                 9 (24)            39 (21)
   Positive test                              1 (1)                1 (2)                   0 (0)             2 (1)
  Complement (C3/C4)                                                                                      
   Negative test                             60 (75)              48 (73)                 27 (71)           135 (73)
   No test                                   19 (24)              17 (26)                 11 (29)           47 (26)
   Positive test                              1 (1)                1 (2)                   0 (0)             2 (1)
  PSA                                                                                                     
   Negative test                             11 (14)              13 (20)                 10 (26)           34 (18)
   No test                                   68 (85)              53 (80)                 28 (74)           149 (81)
   Positive test                              1 (1)                0 (0)                   0 (0)             1 (1)
  ANCA                                                                                                    
   Negative test                             61 (76)              50 (76)                 31 (82)           142 (77)
   No test                                   19 (24)              16 (24)                 7 (18)            42 (23)
  TFTs                                                                                                    
   Negative test                             30 (38)              18 (27)                 20 (53)           68 (37)
   No test                                   50 (62)              48 (73)                 18 (47)           116 (63)
  CXR                                                                                                     
   Positive test                              3 (4)                1 (2)                   0 (0)             4 (2)
   Negative test                             39 (49)              33 (50)                 21 (55)           93 (51)
   No test                                   38 (48)              32 (48)                 17 (45)           87 (47)
  AXR                                                                                                     
   Negative test                              4 (5)                1 (2)                   1 (3)             6 (3)
   No test                                   76 (95)              65 (98)                 37 (97)           178 (97)
  CT head                                                                                                 
   Negative test                              3 (4)                2 (3)                   3 (8)             8 (4)
   No test                                   77 (96)              64 (97)                 35 (92)           176 (96)
  CT thorax                                                                                               
   Positive test                              0 (0)                1 (2)                   0 (0)             1 (1)
   Negative test                              6 (8)                1 (2)                  5 (13)             12 (7)
   No test                                   74 (92)              64 (97)                 33 (87)           171 (93)
  CT abdomen                                                                                              
   Positive test                              0 (0)                1 (2)                   0 (0)             1 (1)
   Negative test                              2 (2)                1 (2)                   1 (3)             4 (2)
   No test                                   78 (98)              64 (97)                 37 (97)           179 (97)
  CT TAP                                                                                                  
   Positive test                              2 (2)                1 (2)                   0 (0)             3 (2)
   Negative test                             20 (25)              15 (23)                 9 (24)            44 (24)
   No test                                   58 (72)              50 (76)                 29 (76)           137 (74)
  MRI                                                                                                     
   Negative test                              1 (1)                1 (2)                   1 (3)             3 (2)
   No test                                   79 (99)              65 (98)                 37 (97)           181 (98)
  PET                                                                                                     
   Positive test                              0 (0)                1 (2)                   0 (0)             1 (1)
   No test                                  80 (100)              65 (98)                38 (100)           183 (99)
  OGD                                                                                                     
   Positive test                              0 (0)                1 (2)                   0 (0)             1 (1)
   Negative test                             11 (14)              8 (12)                  4 (11)            23 (12)
   No test                                   69 (86)              57 (86)                 34 (89)           160 (87)
  Colonoscopy                                                                                             
   Positive test                              1 (1)                0 (0)                   0 (0)             1 (1)
   Negative test                              7 (9)               8 (12)                  5 (13)            20 (11)
   No test                                   72 (90)              58 (88)                 33 (87)           163 (89)
  Sigmoidoscopy                                                                                           
   Negative test                              0 (0)                0 (0)                   1 (3)             1 (1)
   No test                                  80 (100)             66 (100)                 37 (97)           183 (99)
   USS abdomen                                                                                            
   Negative test                             41 (51)              33 (50)                 20 (53            94 (51)
   No test                                   39 (49)              33 (50)                 18 (47)           90 (49)
  Cystoscopy                                                                                              
   Negative test                              0 (0)                1 (2)                   3 (8)             4 (2)
   No test                                  80 (100)              65 (98)                 35 (92)           180 (98)

All values are presented as *n* (%) unless stated otherwise.

HIV, human immunodeficiency virus; ANA, anti-nuclear antibody; PSA, prostate-specific antigen; ANCA, anti-neutrophil cytoplasmic antibodies; TFTs, thyroid function tests; CXR, chest X-ray; AXR, abdominal X-ray; CT, computed tomography scan; TAP, thorax, abdomen and pelvis; MRI, magnetic resonance imaging; PET, positron emission tomography; OGD, oesophagogastroduodenoscopy; USS, ultrasound scan.

Frequency of anti-PLA~2~R testing
---------------------------------

In 2011, when the anti-PLA~2~R test became available locally, it was only used in 8 of 20 (40%) patients diagnosed with MN. Since that time there has been a steady increase in the number of patients tested for anti-PLA~2~R within 6 months of their biopsy, with 93.3% of patients having the test in 2014 ([Table 3](#sfz036-T3){ref-type="table"} and [Figure 1](#sfz036-F1){ref-type="fig"}).

![Proportion of MN patients with anti-PLA~2~R testing.](sfz036f1){#sfz036-F1}

![Proportion of each investigation with no anti-PLA~2~R testing, a negative anti-PLA~2~R test and a positive anti-PLA~2~R test, based on whether the investigation was positive or negative. C3/C4, complement C3/C4; RF, rheumatoid factor; Hep, hepatitis.](sfz036f2){#sfz036-F2}

###### 

Number of patients per year of biopsy

  Year of biopsy    Number of patients   No anti-PLA~2~R, *n* (%)   anti-PLA~2~R tested, *n* (%)
  ---------------- -------------------- -------------------------- ------------------------------
  2009                      39                  39 (100.0)                    0 (0.0)
  2010                      28                  28 (100.0                     0 (0.0)
  2011                      20                  12 (60.0)                     8 (40.0)
  2012                      43                  23 (53.5)                    20 (46.5)
  2013                      39                  15 (38.5)                    24 (61.5)
  2014                      15                   1 (6.7)                     14 (93.3)

Number of patients who did and did not have an anti-PLA~2~R test within 6 months of the date of biopsy.

Number of investigations
------------------------

There were a total of 1230 investigations performed in all patients, of which only 20 were positive and led to a diagnosis of secondary MN. From 2011 onwards, there is a reduction in the number of investigations performed in anti-PLA~2~R seropositive patients. In 2012, the first full year of anti-PLA~2~R availability, there was a mean of 6.85 tests (95% CI 5.61--8.09) per patient in those with no anti-PLA~2~R testing or a negative test. In the seropositive group, the mean number of tests was 6.59 (95% CI 4.9--8.2). This difference was not statistically significant (P=0.823). In 2014, the mean number of tests performed per patient in the seropositive group decreased to 4.29 tests (95% CI 2.6--6.1) compared with 9.01 in seronegative patients; this represented a significant difference (95% CI 6.6--11.02; P = 0.019; [Table 4](#sfz036-T4){ref-type="table"}).

###### 

Number of tests and cost of tests based on year of biopsy and anti-PLA~2~R test status

  Year of diagnosis           No test or anti-PLA~2~R negative    Anti-PLA~2~R positive    P-value
  -------------------------- ---------------------------------- ------------------------- ---------
  Cost of tests (£)                                                                       
   2009                           220.27 (137.93--315.77)                NA (NA)             NA
   2010                           216.93 (120.46--328.56)                NA (NA)             NA
   2011                            227.07 (85.92--392.93)        497.92 (89.83--909.00)     0.363
   2012                           161.16 (106.45--227.11)        226.39 (111.68--369.71)    0.414
   2013                           225.64 (107.82--395.67)        218.88 (107.62--383.89)    0.946
   2014                           244.11 (109.88--429.97)        132.94 (29.66--309.44)     0.405
  Number of investigations                                                                
   2009                              6.87 (5.90--7.82)                   NA (NA)             NA
   2010                              6.89 (5.57--8.18)                   NA (NA)             NA
   2011                              4.57 (2.75--6.62)             10.03 (5.00--14.5)       0.164
   2012                              6.85 (5.61--8.09)              6.59 (4.90--8.20)       0.823
   2013                              6.44 (5.04--7.88)              8.08 (6.21--9.71)       0.177
   2014                              9.01 (6.60--11.2)              4.29 (2.60--6.10)       0.019

Values presented as mean (95% CI). NA, not available.

Cost of investigations
----------------------

The total cost of investigations within 6 months of biopsy for all patients was £39 177.83 and, of this, £5533.04 was spent on investigations with a result leading to a diagnosis of secondary MN. In patients with no anti-PLA~2~R testing or a negative result, the cost of investigations remained relatively stable over the years at £220.27 (95% CI 137.93--315.77) in 2009 and £244.11 (95% CI 109.88--429.97) in 2014. In patients with a positive anti-PLA~2~R, the cost of investigations decreased each year from its introduction, going from £497.92 (95% CI 89.83--909.00) in 2011 to £132.94 (95% CI 29.66--309.44) in 2014, although the difference in cost per year was not significant between the groups ([Table 4](#sfz036-T4){ref-type="table"}).

DISCUSSION
==========

The majority of patients with a histological diagnosis of MN will have primary MN, an autoimmune disease in which 70--80% are anti-PLA~2~R positive \[[@sfz036-B10]\]. Since its discovery in 2009, our understanding of the condition has vastly improved, with evidence suggesting the pathogenic nature of the antibody \[[@sfz036-B13], [@sfz036-B19]\]. This, coupled with its relative absence in secondary MN \[[@sfz036-B29]\], makes it a valuable biomarker not only for disease activity, but also for diagnosis.

Prior to the development of the anti-PLA~2~R blood test, the diagnosis of PMN was one of exclusion at a cost to patients and the health care system. In our cohort, the vast majority of investigations carried out for this reason were negative, a use of resources that is considerable given MN is one of the most common causes of adult nephrotic syndrome worldwide \[[@sfz036-B1]\].

Here we show that use of the test has increased over the years, with a higher proportion of our patients with a tissue diagnosis of MN undergoing concomitant anti-PLA~2~R testing; 93% of patients in 2014 compared with only 46.5% in 2012. Along with increased use of anti-PLA~2~R testing, there is a corresponding reduction in the number of other investigations being carried out and a reduction in the cost of investigations.

Approximately one-third of patients with a diagnosis of PMN will go into spontaneous remission, most within the first year \[[@sfz036-B30]\]. For this reason, and along with the complications associated with immunosuppression, patients have traditionally been treated with supportive care through inhibition of the renin--angiotensin--aldosterone system for 6 months before considering immunosuppression \[[@sfz036-B7]\]. However, in the anti-PLA~2~R era, more proactive management may be warranted. It has now been shown that seronegative patients or those with low anti-PLA~2~R are more likely to go into spontaneous remission and less likely to suffer from renal decline \[[@sfz036-B13], [@sfz036-B31]\]. Conversely, patients with high anti-PLA~2~R at diagnosis are more likely to have disease progression, worsening renal function and higher levels of proteinuria \[[@sfz036-B13], [@sfz036-B21], [@sfz036-B31]\]. The reduction of anti-PLA~2~R and subsequent reduction in proteinuria has been shown in a number of studies to improve outcomes following treatment \[[@sfz036-B19]\]. It has also long been shown that achieving either partial or complete remission leads to better long-term outcomes \[[@sfz036-B32], [@sfz036-B33]\].

There is still some debate, however, around the benefits of early immunosuppression. In a randomized controlled trial, early immunosuppression did appear to lead to remission quicker than postponing immunosuppressive therapy, with a similar adverse event profile. At the end of the 6-year follow-up, 86% of patients in the early immunosuppression group had achieved remission compared with 67% in the late treatment group. However, there was no statistical difference in serum creatinine, albumin or proteinuria \[[@sfz036-B34]\]. Given the relatively short follow-up time with respect to the long disease course of MN, over time one could speculate that a difference may have been observed. This study was also carried out in the pre-anti-PLA~2~R era when disease severity was based on proteinuria. By utilizing the anti-PLA~2~R titre, those patients with high levels who are unlikely to go into spontaneous remission and have a higher chance of disease progression could have a shorter time to treatment without the need to wait for unnecessary invasive investigations.

As use of the anti-PLA~2~R test becomes more widespread and physician confidence in its ability to differentiate primary from secondary MN and to prognosticate disease progression increases, it has the potential to radically change management practice. As seen in our study, patients traditionally undergo a large number of invasive investigations in order to rule out pathology, and the majority of these understandably come back with nothing abnormal detected. Not only is the cost to the patients' quality of life a consideration, but also the cost to the health care system, with the use of resources that could be diverted elsewhere. This is especially true given that the cost of the anti-PLA~2~R test, currently offered in the UK by the Protein Reference Unit in Sheffield, is £25.81 per sample. This makes it cheaper than many of the investigations patients are currently subjected to.

Our study does have a number of limitations, in particular the likely underestimate of investigations carried out. In the Greater Manchester and Preston region, renal medicine operates in a hub-and-spoke manner, with specialist renal departments centralized in large teaching hospitals and patients transferred or referred in from smaller satellite units around the region. This means that some investigations may well have been carried out in the satellite unit before the patients' transfer of care, and although the majority of these investigations would be expected to be low-cost tests, such as biochemistry, there may be a number of scans and endoscopies that may not have been accounted for. As this was a retrospective analysis based on patient records, another limitation is the unknown societal cost of anti-PLA~2~R testing, for example, the cost of transport or missed workdays. As there is a general trend towards a reduction in the frequency of investigations in those patients undergoing anti-PLA~2~R testing, one could expect to see a reduction in the associated costs to society. However, this would need to be confirmed in a prospective trial. As with any retrospective study, there are inherent limitations involved; a randomized controlled trial to investigate the effect of anti-PLA~2~R testing on the investigative pathway would be ideal. However, given its proven sensitivity and specificity for MN, it would now be unethical to consider the care of a patient with anti-PLA~2~R-positive MN without the use of the antibody level.

The number of positive anti-PLA~2~R tests in our cohort was lower than reported in other studies, with most reporting in the region of 70--80% of MN patients \[[@sfz036-B10], [@sfz036-B14], [@sfz036-B19]\]. There were, however, a large number of patients in the earlier years of its use that were not tested. As the test became more ubiquitous over time, the percentage of positive samples better reflected the literature. For example, in 2014 there were 14 anti-PLA~2~R tests, of which 10 were positive, representing 71% of patients.

The use of anti-PLA~2~R is not infallible, with a number of case reports identifying patients with secondary MN and elevated anti-PLA~2~R \[[@sfz036-B35]\]. Whether this is coincidental, given that patients in the age group most affected by MN are also at risk of malignancy, is yet to be proven conclusively. Each patient still needs a careful and thorough history and examination and investigation as appropriate.

Saying this, as the anti-PLA~2~R test becomes commonplace in patients with nephrotic syndrome, its use can help to reduce the burden of investigations for both the patient and society and its use should be included in future management guidelines and research.
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